Preclinical Trial Equipment Supplied In Europe

ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in Phase 2a and Phase 2b induction trials to treat ulcerative colitis (UC). Patients who completed the induction studies had the option to roll over into the respective open-label extension ...

The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule. ...

Using the latest tools in bioengeneering, our researchers are now printing cancer tissues in 3D. These models can be used for highly significant pre-clinical trials and can be produced in 6/48/96 well plates for high throughput ...

A new in silico tool for early screening of compounds multicurrent blocking effects on a population of hiPSC-derived ...

The RSOM Explorer P50 consists of a compact mobile cart system with a light-tight imaging chamber including a live-view camera for experiment supervision and a heated animal bed with integrated anesthesia supply. While raster-scanning the field of view, a nanosecond pulsed 532 nm laser excites the tissue. The induced ultrasound signal is detected by a broadband transducer with 50 MHz center ...

The aXess graft is a restorative, synthetic, electrospun blood vessel for arteriovenous hemodialyisis access, overtime turning into a living vessel made of patient’s own ...

Vectisol® is dedicated to the preservation of organs, tissues and cells. This molecular complex limits the deleterious effects of the ischemia-reperfusion ...

IVX-121 targets respiratory syncytial virus (RSV), a major cause of viral pneumonia for which no vaccine has been FDA approved. IVX-121 incorporates a stabilized prefusion F antigen licensed from NIAID/NIH (DS-Cav1; Science 2019). RSV F is known to undergo major structural changes that allow viral entry into the host cell, and during that process, critical protective epitopes are lost. Protein ...

Wolfmet 3D, developed by M&I Materials Ltd, leverages a sophisticated selective laser melting (SLM) technique for additive manufacturing. This process involves the use of a high-powered laser to meticulously fuse layers of pure tungsten powder. The result is the creation of highly intricate and precise components such as collimators and radiation shields used in medical imaging systems like ...

AM-125 for the treatment of vertigo is expected to complete its Phase 2 TRAVERS trial in Q2 2022 and to move into Phase 3 in Q4 2022. Keyzilen® (AM-101) for the treatment of acute inner ear tinnitus and Sonsuvi® (AM-111) for the treatment of acute inner ear hearing loss have both been evaluated in Phase 3 trials, but will require further clinical testing. ...

Plasmid DNA in reproducible and certified quality for preclinical and veterinary research. Cultivation without use of animal derived media. Controlled removal of bacterial LPS endotoxins. Complete removal of RNA and proteins. A large number of quality tests already inclusive – without any additional ...

Therapeutic area: cancer vaccines; Systemic, intravenous (IV) ...

New generation of oral bioactives to treat inflammatory and autoimmune diseases. EndoMimicsTM are first-in-class orally available bioactives drugs based on proteins secreted by the gut bacteria that act like human hormones or cytokines. Enterome expects partnering to play a central in generating value from its EndoMimics pipeline. ...

Fully synthetic restorative pulmonary heart valve for Right Ventricular Outflow Tract reconstruction, overtime turning into a living heart valve made of patient’s own ...

K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...

An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer ...

MagnetOs isn’t like other bone grafts. It grows bone even in soft tissue thanks to our unique NeedleGrip™ surface technology which provides traction for our body’s vitally important ‘pro-healing’ immune cells (M2 macrophages).*†6,7 This in turn, unlocks previously untapped potential to stimulate stem cells – and form new bone throughout the graft.*8-10 ...

Alomfilimab SAR445256 (formerly KY1044) is a human monoclonal IgG1 that selectively binds to Inducible T cell CO-stimulator (ICOS), a protein expressed at high levels on immunosuppressive regulatory T cells and at lower levels on effector T cells. Alomfilimab is designed to exert anti-tumour activity through preferential depletion of intra-tumoral regulatory T cells and stimulation (agonism) of ...

Direct Sodium Removal (DSR®) therapy is Sequana Medical’s novel and proprietary approach under development for the management of fluid overload due to heart failure. The sodium concentration in patients with fluid overload is in balance but there is too much sodium and too much fluid in the body. Sequana Medical’s approach is to remove excess sodium in patients with ...

Our mRNA platforms and vast in-house experience help partners quickly optimize, screen and select an mRNA code, develop a candidate, and ensure effective & prime manufacturing of the mRNA from research grade to GMP scale. Our platform’s scale and flexibility is uniquely suited to respond to the needs of development partners across a wide range of therapeutic ...